Ai's Potential: Revolutionizing Clinical Trials and Longevity

WHO:

Bloomberg - Kiran Mazumdar-Shaw, Executive Chairperson of Biocon

Fast Company - Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine

WHAT:

Bloomberg - Kiran Mazumdar-Shaw stated that AI can abbreviate long, expensive clinical trials by predicting safety and efficacy.

Fast Company - AI may eventually help double human lifespan, according to Alex Zhavoronkov.

Fast Company - The drug rentosertib was developed for idiopathic pulmonary fibrosis and reached a nominated preclinical candidate in 18 months.

Fast Company - A Phase IIa study of rentosertib reported an encouraging lung-function signal, and the program has advanced to Phase III testing.

WHERE:

Bloomberg - The comments by Kiran Mazumdar-Shaw were made at the Bloomberg New Economy Forum in New Delhi.

WHEN:

Fast Company - The Phase III testing of rentosertib is ongoing.

WHY:

Bloomberg - The wave of expiring biologic patents provides a major runway to expand affordable cancer biosimilars.

Fast Company - AI is giving longevity research a new way forward by providing better tools to identify potential interventions and investigate their effects.

HOW:

Bloomberg - AI accelerates molecular discovery.

Fast Company - AI can analyze biological data, identify potential drug targets, generate chemical structures, and help scientists decide which experiments to run.

Fast Company - The Nature Biotechnology analysis applied six proteomic aging clocks to blood samples from a subset of rentosertib trial participants to estimate biological age from patterns of circulating proteins.

(UPDATED October 15, 2026 10:01 UTC)

At the Bloomberg New Economy Forum in New Delhi, Kiran Mazumdar-Shaw emphasized that AI has the potential to significantly shorten clinical trials by predicting both safety and efficacy. Meanwhile, Alex Zhavoronkov, founder and CEO of Insilico Medicine, suggested that AI could eventually help double human lifespan, highlighting the promising advancements in longevity research. The ongoing Phase III testing of the drug rentosertib, developed for idiopathic pulmonary fibrosis, has shown encouraging results in lung function, showcasing the power of AI in accelerating molecular discovery and identifying effective drug targets.